Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...

In the draft guidance published on 23 February, the FDA specifically discusses genome editing and RNA-based therapies that are highly specific, personalised therapies. Credit: H_Ko/Shutterstock.com ...

Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...

Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...

The North Midlands CRDC has recruited its first patient, representing the UK’s initial participation in a clinical trial of ...

Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.

Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the ...

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

CStone Pharmaceuticals' IND application has received FDA clearance, enabling the company to initiate a Phase II trial of its trispecific antibody CS2009.

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.